SETD2 and breast cancer: To determine whether tumor ascorbate levels vary in breast cancer and whether levels are associated with HIF-1 activation, we have undertaken a retrospective analysis of breast cancer tissues to quantify the ascorbate content in tumor and adjacent uninvolved breast tissue harvested from breast cancer patients at surgery.